Intervention

Talazoparib

ClinicalTrials.gov intervention label

Clinical trials41
Recruiting6
Common conditions25
Lead sponsors shown15

Clinical trials

41 shown
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or DarolutamideNCT06844383 · 2026-05-04
RECRUITING
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate CancerNCT05873192 · 2025-06-03
RECRUITING
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical TrialNCT03990896 · 2021-11-18
RECRUITING
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate CancerNCT04734730 · 2021-05-04
RECRUITING
Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)NCT05035745 · 2021-03-01
RECRUITING
FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) TestNCT06193525 · 2019-09-16
RECRUITING
Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate CancerNCT05425862 · 2022-10-21
SUSPENDED
Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) SignatureNCT05288127 · 2022-03-08
UNKNOWN
Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2mNCT05141708 · 2021-12-17
COMPLETED
A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast CancerNCT04690855 · 2021-10-04
TERMINATED
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid TumorsNCT04991480 · 2021-09-13
COMPLETED
Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast CancerNCT04849364 · 2021-08-24
TERMINATED
Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast CancerNCT04987931 · 2021-08-20
COMPLETED
Telaglenastat + Talazoparib In Prostate CancerNCT04824937 · 2021-07-01
UNKNOWN
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPCNCT04846478 · 2021-06-28
ACTIVE_NOT_RECRUITING
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair VariationsNCT04550494 · 2021-04-26
ACTIVE_NOT_RECRUITING
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian CancerNCT04703920 · 2021-03-04
COMPLETED
Talazoparib Maintenance Therapy in Triple-negative Breast CancerNCT04755868 · 2021-03-01
UNKNOWN
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyNCT04591431 · 2020-10-07
UNKNOWN
Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)NCT04332744 · 2020-09-02
COMPLETED
Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOtheliomaNCT04462809 · 2020-09-01
UNKNOWN
Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive BiomarkerNCT04334941 · 2020-07-20
ACTIVE_NOT_RECRUITING
Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast CancerNCT04134884 · 2020-04-01
COMPLETED
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)NCT04173507 · 2020-02-14
COMPLETED
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.NCT04039230 · 2019-10-09
ACTIVE_NOT_RECRUITING
A Study of the Drugs Talazoparib and Temozolomide in Prostate CancerNCT04019327 · 2019-07-11
TERMINATED
A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast CancerNCT03901469 · 2019-06-26
TERMINATED
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid TumorsNCT03875313 · 2019-05-20
TERMINATED
TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast CancerNCT03964532 · 2019-04-19
ACTIVE_NOT_RECRUITING
Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast CancersNCT03911973 · 2019-04-17
ACTIVE_NOT_RECRUITING
Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung CancerNCT03672773 · 2018-10-31
ACTIVE_NOT_RECRUITING
A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate CancerNCT03148795 · 2017-07-04
COMPLETED
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung CancerNCT03377556 · 2017-03-03
COMPLETED
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney DysfunctionNCT02567396 · 2016-06-01
WITHDRAWN
Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast CancerNCT02627430 · 2016-03-01
WITHDRAWN
Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid TumorsNCT02537561 · 2015-12-01
WITHDRAWN
Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast CancerNCT02282345 · 2015-04-16
COMPLETED
Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA GenesNCT02286687 · 2014-12-22
ACTIVE_NOT_RECRUITING
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung CancerNCT02154490 · 2014-07-08
COMPLETED
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid TumorsNCT01286987 · 2011-01-03
COMPLETED
Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)NCT05650476
AVAILABLE

Common conditions

Breast Cancer8Triple Negative Breast Cancer5Prostate Cancer4HER2/Neu Negative3Metastatic Breast Cancer3Metastatic Castration-resistant Prostate Cancer3TNBC - Triple-Negative Breast Cancer3ATM Gene Mutation2BRCA1 Gene Mutation2BRCA2 Gene Mutation2Breast Neoplasms2Estrogen Receptor Negative2Metastatic Ovarian Carcinoma2Metastatic Prostate Cancer2PALB2 Gene Mutation2Progesterone Receptor Negative2Prostate Cancer Metastatic2Recurrent Breast Carcinoma2Recurrent Ovarian Carcinoma2Recurrent Squamous Cell Lung Carcinoma2Stage IV Prostate Cancer AJCC v82Stage IV Squamous Cell Lung Carcinoma AJCC v72Triple-Negative Breast Carcinoma2Adult Solid Neoplasm1Advanced Breast Cancer1

Trial status mix

COMPLETED12
ACTIVE_NOT_RECRUITING8
RECRUITING6
TERMINATED5
UNKNOWN5
WITHDRAWN3
AVAILABLE1
SUSPENDED1

Phase mix

PHASE228
PHASE115

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.